


Boceprevir-d₉

Cat. No.:	HY-10237S
CAS No.:	1256751-11-7
Molecular Formula:	C ₂₇ H ₃₆ D ₉ N ₅ O ₅
Molecular Weight:	528.73
Target:	HCV Protease; SARS-CoV; HCV; Isotope-Labeled Compounds
Pathway:	Anti-infection; Metabolic Enzyme/Protease; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Boceprevir-d ₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Njoroge FG, et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. *Acc Chem Res.* 2008 Jan;41(1):50-9.
- [3]. Coilly A, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. *Antimicrob Agents Chemother.* 2012 Nov;56(11):5728-34.
- [4]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. *Signal Transduct Target Ther.* 2021 May 29;6(1):212.
- [5]. Yao M, et al. Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity. *PLoS One.* 2016 Mar 4;11(3):e0150894.
- [6]. Berenguer M, et al. New developments in the management of hepatitis C virus infection: focus on boceprevir. *Biologics.* 2012;6:249-56.
- [7]. Burton MJ, et al. Telaprevir and boceprevir in african americans with genotype 1 chronic hepatitis C: implications for patients and providers. *South Med J.* 2012 Aug;105(8):431-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA